amlodipine has been researched along with Dyslipidemia in 34 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Excerpt | Relevance | Reference |
---|---|---|
"We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 9.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
"This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia." | 9.34 | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020) |
"Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies." | 9.30 | Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019) |
"Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 9.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
"This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
"Early and sustained improvement in small artery compliance was observed following coadministration of amlodipine and atorvastatin, thus demonstrating a vascular benefit with simultaneous treatment of hypertension and dyslipidemia." | 9.14 | Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009) |
" The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy." | 9.12 | A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007) |
"The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia." | 9.12 | Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006) |
"- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk." | 7.88 | EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018) |
"We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)." | 7.76 | [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010) |
" There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 7.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
" The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up." | 6.94 | Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020) |
" The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 6.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
"We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 5.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
"Hypertension and dyslipidemia are important risk factors for cardiovascular disease." | 5.56 | Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020) |
"This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia." | 5.34 | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020) |
"Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies." | 5.30 | Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019) |
"Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 5.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
" In this study, we investigated the effects of valsartan and amlodipine on the lipid profile in patients with newly diagnosed essential hypertension." | 5.17 | An additional LDL-lowering effect of amlodipine; not only an antihypertensive? ( Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H, 2013) |
"This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
"Single-pill amlodipine/atorvastatin targets the two most common modifiable cardiovascular risk factors, hypertension and dyslipidaemia." | 5.14 | International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. ( Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD, 2009) |
"The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia." | 5.14 | Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). ( Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF, 2009) |
"Early and sustained improvement in small artery compliance was observed following coadministration of amlodipine and atorvastatin, thus demonstrating a vascular benefit with simultaneous treatment of hypertension and dyslipidemia." | 5.14 | Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009) |
"The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia." | 5.12 | Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006) |
" The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy." | 5.12 | A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007) |
"- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk." | 3.88 | EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018) |
"Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia." | 3.88 | [THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]. ( Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K, 2018) |
"the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks." | 3.81 | Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study. ( Abdillah, A; Kalim, H; Setiawati, A, 2015) |
"We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)." | 3.76 | [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010) |
" There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 3.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
" The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up." | 2.94 | Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020) |
" The primary objective of the study was to determine the effect of once-daily dosing of a combination therapy for blood pressure (BP) and dyslipidemia using home BP monitoring on reaching clinical BP and the effect of daily dosing of combination therapy on reaching lipid goals." | 2.76 | Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. ( Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S, 2011) |
" The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 2.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
"Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition." | 2.45 | Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. ( Bangalore, S; Devabhaktuni, M, 2009) |
"Hypertension and dyslipidemia are important risk factors for cardiovascular disease." | 1.56 | Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020) |
"5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification." | 1.51 | Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. ( Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M, 2019) |
"Our objective was to describe prescribing patterns of simvastatin in combination with medications known to increase the risk of myopathies following updated product labeling dosing restrictions in June 2011." | 1.42 | Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. ( Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM, 2015) |
"Cardiovascular diseases are the leading cause of death worldwide." | 1.39 | Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. ( Ivanovic, B; Tadic, M, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (29.41) | 29.6817 |
2010's | 18 (52.94) | 24.3611 |
2020's | 6 (17.65) | 2.80 |
Authors | Studies |
---|---|
Kim, MC | 1 |
Ahn, Y | 2 |
Kim, MH | 2 |
Kim, SY | 3 |
Hong, TJ | 1 |
Rhee, MY | 3 |
Kim, SH | 1 |
Hong, SJ | 3 |
Kim, H | 2 |
Kim, W | 2 |
Chae, IH | 2 |
Kang, DH | 2 |
Kim, BK | 1 |
Kim, HS | 3 |
Jung, HW | 1 |
Kim, CY | 1 |
Hong, SP | 2 |
Bae, HJ | 1 |
Choi, JY | 1 |
Ryu, JK | 1 |
Lee, JB | 1 |
Lee, KH | 1 |
Han, KR | 1 |
Yang, DH | 1 |
Park, CG | 3 |
Yu, GW | 1 |
Park, SJ | 1 |
Hyon, MS | 3 |
Shin, JH | 3 |
Hong, BK | 1 |
Jin, HY | 1 |
Lee, SY | 1 |
Seol, SH | 1 |
Lee, SR | 1 |
Lee, KJ | 1 |
Cho, EJ | 4 |
Nam, CW | 1 |
Park, TH | 1 |
Kim, U | 2 |
Kim, KS | 1 |
Perrone, V | 1 |
Veronesi, C | 1 |
Gambera, M | 1 |
Nati, G | 1 |
Perone, F | 1 |
Tagliabue, PF | 1 |
Degli Esposti, L | 1 |
Volpe, M | 1 |
Sofogianni, A | 1 |
Tziomalos, K | 1 |
Chang, K | 2 |
Ahn, JC | 2 |
Yu, CW | 1 |
Cho, KI | 1 |
Kim, YJ | 1 |
Lee, SH | 2 |
Kim, SJ | 1 |
Ahn, YK | 1 |
Lee, CH | 1 |
Kim, M | 1 |
Lin, CP | 1 |
Tung, YC | 1 |
Hsiao, FC | 1 |
Yang, CH | 1 |
Kao, YW | 1 |
Lin, YS | 1 |
Chu, YC | 1 |
Chu, PH | 1 |
Jin, X | 1 |
Han, KH | 1 |
Sung, JH | 1 |
Cho, JM | 2 |
Lee, HC | 1 |
Choi, SY | 1 |
Lee, K | 1 |
Kim, WS | 1 |
Kim, JH | 2 |
Yoo, BS | 1 |
Lee, JH | 2 |
Kim, PJ | 1 |
Sung, KC | 1 |
Hwang, J | 1 |
Kwon, K | 1 |
Seo, JS | 1 |
Lee, H | 1 |
Cho, Y | 1 |
Tabukashvili, R | 1 |
Kapetivadze, V | 1 |
Tchaava, K | 1 |
Gegeshidze, N | 1 |
Lazashvili, T | 1 |
Maglapheridze, Z | 1 |
Jeong, HS | 1 |
Pyun, WB | 1 |
Kang, WC | 1 |
Naydenov Naydenov, S | 1 |
Margaritov Runev, N | 1 |
Ivanov Manov, E | 1 |
Georgieva Torbova-Gigova, S | 1 |
Ivanovic, B | 1 |
Tadic, M | 1 |
Sutradhar, S | 3 |
Yunis, C | 3 |
Westergaard, M | 1 |
Tuchscherer, RM | 1 |
Nair, K | 1 |
Ghushchyan, V | 1 |
Saseen, JJ | 1 |
Galeeva, ZM | 1 |
Galiavich, AS | 1 |
Setiawati, A | 1 |
Kalim, H | 1 |
Abdillah, A | 1 |
Ferket, BS | 1 |
Hunink, MG | 1 |
Khanji, M | 1 |
Agarwal, I | 1 |
Fleischmann, KE | 1 |
Petersen, SE | 1 |
Erdine, S | 1 |
Ro, YM | 1 |
Tse, HF | 1 |
Howes, LG | 1 |
Aguilar-Salinas, CA | 1 |
Chaves, H | 1 |
Guindy, R | 1 |
Chopra, P | 1 |
Moller, RA | 1 |
Schou, IM | 1 |
Cohn, JN | 1 |
Wilson, DJ | 1 |
Neutel, J | 1 |
Houston, M | 1 |
Weinberger, MH | 1 |
Grimm, R | 2 |
Smith, DH | 1 |
Sun, W | 2 |
Neutel, JM | 2 |
Bestermann, WH | 1 |
Dyess, EM | 1 |
Graff, A | 1 |
Kursun, A | 2 |
Richard Hobbs, FD | 1 |
Gensini, G | 2 |
John Mancini, GB | 1 |
Manolis, AJ | 2 |
Bauer, B | 2 |
Genest, J | 2 |
Feldman, RD | 1 |
Harvey, P | 3 |
Jenssen, TG | 2 |
da Silva, PM | 2 |
Devabhaktuni, M | 1 |
Bangalore, S | 1 |
Curran, MP | 1 |
Malik, M | 1 |
Lopatin, IuM | 1 |
Abrashkina, ED | 1 |
Shaalali, N | 1 |
Pakhrova, OA | 1 |
Shutemova, EA | 1 |
Nazarova, OA | 1 |
Yamamoto, K | 1 |
Ozaki, H | 1 |
Takayasu, K | 1 |
Akehi, N | 1 |
Fukui, S | 1 |
Sakai, A | 1 |
Kodama, M | 1 |
Shimonagata, T | 1 |
Kobayashi, K | 1 |
Ota, M | 1 |
Horiguchi, Y | 1 |
Ebisuno, S | 1 |
Katsube, Y | 1 |
Yamazaki, T | 1 |
Ohtsu, H | 1 |
Hori, M | 1 |
Oliver, S | 1 |
Jones, J | 1 |
Leonard, D | 1 |
Crabbe, A | 1 |
Delkhah, Y | 1 |
Nesbitt, S | 1 |
Delgado-Montero, A | 1 |
Zamorano, JL | 1 |
Arslan, Z | 1 |
Ay, SA | 1 |
Karaman, M | 1 |
Cakar, M | 1 |
Celik, T | 1 |
Balta, S | 1 |
Akhan, M | 1 |
Sarlak, H | 1 |
Arslan, E | 1 |
Demirbas, S | 1 |
Demirkol, S | 1 |
Bulucu, F | 1 |
Saglam, K | 1 |
Hobbs, FD | 1 |
Mancini, GB | 1 |
Böhler, S | 1 |
Feldman, R | 1 |
Metcalfe, M | 1 |
Blank, R | 1 |
Messerli, FH | 1 |
Bakris, GL | 1 |
Ferrera, D | 1 |
Houston, MC | 1 |
Petrella, RJ | 1 |
Flack, JM | 1 |
Lee, E | 1 |
Preston, RA | 1 |
Herfert, O | 1 |
Dykstra, G | 1 |
Jukema, JW | 1 |
Sun, F | 1 |
Gillen, D | 1 |
McKeage, K | 1 |
Siddiqui, MA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension[NCT03103256] | Phase 3 | 106 participants (Actual) | Interventional | 2017-05-17 | Completed | ||
A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Temisartan/Amlodipine and Rosuvastatin in Subjects With Hypertension and Hyperlipidemia[NCT03067688] | Phase 3 | 202 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension[NCT03088254] | Phase 3 | 126 participants (Actual) | Interventional | 2016-09-20 | Completed | ||
Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)[NCT00174304] | Phase 4 | 1,120 participants | Interventional | 2004-10-31 | Completed | ||
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)[NCT00330785] | Phase 3 | 1,250 participants | Interventional | 2004-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
5 reviews available for amlodipine and Dyslipidemia
Article | Year |
---|---|
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases | 2009 |
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseas | 2010 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dysl | 2012 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blocker | 2006 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Disease | 2008 |
17 trials available for amlodipine and Dyslipidemia
Article | Year |
---|---|
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipid | 2023 |
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.
Topics: Amlodipine; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Hypertension | 2023 |
A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; | 2020 |
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; D | 2020 |
Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2019 |
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases; | 2014 |
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, D | 2014 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardi | 2009 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemia | 2009 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarker | 2010 |
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African Americ | 2011 |
An additional LDL-lowering effect of amlodipine; not only an antihypertensive?
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2013 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholest | 2006 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2007 |
12 other studies available for amlodipine and Dyslipidemia
Article | Year |
---|---|
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; B | 2019 |
Fixed-dose combinations of lipid-lowering and antihypertensive agents: The way forward?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Dyslipidemias; Humans; Hyp | 2020 |
Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Drug Therapy, Combination; Dys | 2020 |
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dysl | 2018 |
EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cholesterol; Ch | 2018 |
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combin | 2013 |
Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
Topics: Amlodipine; Calcium Channel Blockers; Comorbidity; Drug Interactions; Drug Labeling; Drug Prescripti | 2015 |
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Sub | 2015 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com | 2017 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic | 2010 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; | 2010 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiov | 2006 |